



# Surveillance in Europe – Experience and Lessons from the Pandemic in Europe

**Prof Angus Nicoll CBE European Centre for Disease Prevention and Control**

**Ministry of Health, China - International Scientific Symposium on Influenza A(H1N1) Pandemic Preparedness and Response August 21<sup>st</sup> 2009, Beijing, China**

# Working Arm in Arm with WHO and the European Commission on Pandemic Preparedness since 2005




# Plan of Talk



- *It could be a lot worse*
- Epidemiological findings to date in Europe
- How surveillance had to adapt
- Importance of a rolling forward looking risk assessment
- Containment vs. Mitigation – a mention
- Schools – a mention
- Importance of the health care sector
- Preparing for a tough autumn and winter
- Preparing for the vaccine – a mention

[http://ecdc.europa.eu/en/healthtopics/Pages/Influenza\\_A\(H1N1\)\\_Outbreak.aspx](http://ecdc.europa.eu/en/healthtopics/Pages/Influenza_A(H1N1)_Outbreak.aspx)



# The situation could be a lot worse (Situation circa summer 2009)



- A pandemic strain emerging in the Americas. A pandemic emerging in less prepared countries
- Immediate virus sharing so rapid diagnostic and vaccines. Delayed virus sharing
- Pandemic (H1N1) currently not that pathogenic. Based on a more pathogenic strain, e.g. A(H5N1)
- Some seeming residual immunity in a major large risk group (older people). No residual immunity
- No known pathogenicity markers. Heightened pathogenicity
- Initially susceptible to oseltamivir. Inbuilt antiviral resistance
- Good data and information coming out of North America. Minimal data until transmission reached Europe
- Arriving in Europe in the summer. Arriving in the late autumn or winter
- Mild presentation in most. Severe presentation immediately

**Contrast with what might have happened — and might still happen!**

## The story from surveillance so far for Europe

*Remember this is happening in the late spring and summer when influenza does not transmit well*


- Initial imported cases from the Americas
- Then transmission in all European countries
- But very heterogeneous distribution across and within countries
- Schools were important for detecting transmission through outbreaks
- Most people experience only a mild disease
- Mostly young cases cf. seasonal influenza
- But cases going to and staying in hospital are older
- Cases getting very sick and dying mostly have underlying disease
- Minimal antiviral resistance so far despite a lot of use
- The worst is yet to come for Europe



**Some Surveillance Outputs –  
which illustrate some errors and  
improvements that are needed**


# When we were counting cases – probably a mistake but unavoidable – early May

Reported cumulative number of confirmed cases of influenza A(H1N1) virus in EU and EFTA countries, as of 09 May 2009, 8:00 hours CEST




# By Late July ---

Reported cumulative number of confirmed cases of influenza A(H1N1)v in EU and EFTA countries, as of 31 July 2009, 16:00 hours CEST



# In August a switch to deaths – but will underestimate the attributable excess deaths?

Reported cumulative number of confirmed fatal cases of influenza A(H1N1)v in EU and EFTA countries, as of 18 August 2009, 16:00 hours CEST




**Table 1: Reported new confirmed cases and cumulative number of influenza A(H1N1)v and cumulative deaths among confirmed cases by country as of 19 August 2009, 16:00 hours (CEST) in the EU and EFTA countries**

Country	Confirmed cases reported in the last 24h	Cumulative number of confirmed cases	Deaths among confirmed cases <sup>a</sup>
Austria	-	222	-
Belgium	-	126	1
Bulgaria	6	57	-
Cyprus	-	297	-
Czech Republic	-	209	-
Denmark	-	444	-
Estonia	1	57	-
Finland	4	204	-
France <sup>b</sup>	-	1125	1
Germany	337	12830	-
Greece	-	1424	-
Hungary	2	145	1
Iceland	-	135	-
Ireland	-	574	2
Italy	-	1238	-
Latvia	-	23	-
Liechtenstein	-	5	-
Lithuania	-	40	-
Luxemburg	-	118	-
Malta	-	231	1
Netherlands <sup>c</sup>	-	1473	1
Norway	-	868	-
Poland	2	152	-
Portugal	257	1634	-
Romania	7	269	-
Slovakia	1	99	-
Slovenia	1	203	-
Spain	-	1538	12
Sweden	70	672	-
Switzerland	41	841	-
United Kingdom <sup>d</sup>	-	12903	44
<b>Total</b>	<b>729</b>	<b>40156</b>	<b>63</b>

Note: cases reported in the EU and EFTA countries correspond to the EWRS notifications by Member States or Ministry of Health websites. *Countries shaded with gray are not recommending laboratory tests for all suspect cases, therefore comparisons in time or between these countries should not be made at present.*



# Age distribution of A(H1N1)v cases by gender (n=8541), 28 EU/EEA countries, 19 April- 3 August 2009




## **Data from the most affected country in Europe – UK**


**– thanks to the Department of Health, the Health Protection Agency, the NHS and the devolved Administrations**



# RCGP (England and Wales) ILI consultation rate per 100,000 2008/09 and recent seasons.



# Age distribution of A(H1N1)v cases by gender (n=8541), 28 EU/EEA countries, 19 April- 3 August 2009





# Switching to more conventional influenza surveillance and building on what we have in Europe

**Surveillance Planning Meeting with WHO and input from other experienced countries – July 14-15<sup>th</sup>**

[http://ecdc.europa.eu/en/publications/Publications/0908\\_MER\\_Surveillance\\_and\\_Studies\\_in\\_a\\_Pandemic\\_Meeting\\_Report.pdf](http://ecdc.europa.eu/en/publications/Publications/0908_MER_Surveillance_and_Studies_in_a_Pandemic_Meeting_Report.pdf)

# Building on existing surveillance and studies



## **In all countries:**

Relying on sentinel surveillance

Relying on virological surveillance

Case reporting of severe cases and deaths (SARI)

## **In some countries:**

Hospital surveillance and monitoring Important

Monitoring mortality in real time


Special studies

linking modelling, surveillance and decision making

Preparing for estimating effectiveness of vaccines

Preparing for surveillance for adverse effects of vaccine & antivirals

[http://ecdc.europa.eu/en/publications/Publications/0908\\_MER\\_Surveillance\\_and\\_Studies\\_in\\_a\\_Pandemic\\_Meeting\\_Report.pdf](http://ecdc.europa.eu/en/publications/Publications/0908_MER_Surveillance_and_Studies_in_a_Pandemic_Meeting_Report.pdf)



## A Rolling Risk Assessment

[http://ecdc.europa.eu/en/healthtopics/Documents/0907\\_Influenza\\_AH1N1\\_Risk\\_Assessment.pdf](http://ecdc.europa.eu/en/healthtopics/Documents/0907_Influenza_AH1N1_Risk_Assessment.pdf)

## Leading to Revised Planning projections

[http://ecdc.europa.eu/en/healthtopics/Documents/0908\\_InfluenzaA\\_H1N1\\_Planning\\_Assumptions\\_for\\_the\\_First\\_Wave\\_of\\_Pandemic\\_A\(H1N1\)\\_2009\\_in\\_Europe.pdf](http://ecdc.europa.eu/en/healthtopics/Documents/0908_InfluenzaA_H1N1_Planning_Assumptions_for_the_First_Wave_of_Pandemic_A(H1N1)_2009_in_Europe.pdf)



# Some revised planning assumptions for the pandemic – first wave A(H1N1) 2009


These represent a **reasonable worst case** from the most affected country (the United Kingdom) with data available as of July 2009 They should not be used for predictions

Source: UK [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_102892](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_102892)



Clinical attack rate	30%
Peak clinical attack rate	6.5% (local planning assumptions 4.5% to 8%) per week
Complication rate	15% of clinical cases
Hospitalisation rate	2% of clinical cases
Case fatality rate	0.1% to 0.2% (cannot exclude up to 0.35%) of clinical cases
Peak Absence Rate	12% of workforce

# One possible European scenario — autumn and winter 2009 (selected countries)



# Policy dilemma – mitigating vs. attempting delaying (containing) pandemics?



Arguments for just mitigating and not attempting delaying or containment:

- Containment specifically not recommended by WHO in Phases 5 & 6.
- Was not attempted by the United States for this virus.
- Delaying or containment cannot be demonstrated to have worked
- **Very labour-intensive — major opportunity costs.**
- Will miss detecting sporadic transmissions.
- Overwhelming numbers as other countries 'light up'.
- **When you change tactic, major communication challenge with stopping prophylaxis**
- **Proactive school closures rarely feasible and operationally impossible in Europe with this pandemic virus**

<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19279>

Cauchemez S et al .(2009) Closing schools during an influenza pandemic: A review. Lancet Infectious Diseases Vol. 9 No. 8 pp 473-481

[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(09\)70176-8/abstract](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(09)70176-8/abstract)

# Conclusions



- **Five years preparation have paid off**
- **But need to operationalise and adapt the plans for this specific pandemic**
- **Surveillance has had to be adjusted**
- **Built around a regularly updated risk assessment**
- **Planning projections has to be adjusted**
- **Personal interventions - are justified**
- **Societal Public Health Interventions – mostly not justified**
- **Containment vs. Mitigation - Don't try to contain**
- **Beware of stating numbers – numbers of deaths are difficult**
- **The health care sector is the vulnerable point**

[http://ecdc.europa.eu/en/healthtopics/Pages/Influenza\\_A\(H1N1\)\\_Outbreak.aspx](http://ecdc.europa.eu/en/healthtopics/Pages/Influenza_A(H1N1)_Outbreak.aspx)

# Acknowledgements



All European Member States  
European Commission DG SANCO  
National Influenza Centres  
European Influenza Surveillance  
Network members  
Clinicians and microbiologists  
WHO Headquarters  
WHO Regional Office for Europe  
Department of Health UK  
Health Protection Agency and  
Devolved Administrations UK  
United States CDC  
ECDC Advisory Forum  
ECDC Colleagues

## **Individuals who contributed personally to this presentation:**

Andrea Ammon  
Andrew Amato  
Sylvie Briand  
Denis Coulombier  
Isabelle Devaux  
Liam Donaldson  
Johan Giesecke  
Didier Houssin  
Uwe Kweisel  
Tony Mounts  
Pasi Penttinen  
Helen Shirley-Quirk  
John Watson  
Maria Zambon

